Please login to the form below

Not currently logged in
Email:
Password:

Zocor

This page shows the latest Zocor news and features for those working in and with pharma, biotech and healthcare.

FDA panel rejects cardiovascular outcomes claim for Vytorin

FDA panel rejects cardiovascular outcomes claim for Vytorin

expire. Vytorin has been a somewhat controversial product for Merck since the publication of the ENHANCE trial, which compared the drug to simvastatin (Merck's now off-patent brand Zocor) alone

Latest news

More from news
Approximately 1 fully matching, plus 39 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics